According to various sources in the industry, AstraZeneca China's biopharmaceutical business BBU and omnichannel business unit structure will undergo a series of adjustments on October 1 this year.
AstraZeneca China's biopharmaceutical business and omnichannel business unit will be officially merged to form a new AstraZeneca China biopharmaceutical business (BBU).
Merge the respiratory inhalation business unit, respiratory atomization business unit and digestive business unit to form the respiratory digestive business unit; merge the biologics business unit, vaccines and immunotherapy, and autoimmune business unit; merge the biologics business unit, vaccines and immunotherapy, and autoimmune business unit to form the respiratory and autoimmune biopharmaceuticals, vaccines and immunotherapy business units.
According to incomplete statistics, this is at least the third adjustment of AstraZeneca China this year. "Adjustment" seems to be the key to AstraZeneca China's performance development. AstraZeneca once said that the new map will add momentum to the long-term development of its business.
At the beginning of this year, AstraZeneca China established the Chinese biopharmaceutical business. Lin Xiao is appointed as the general manager of AstraZeneca's China biopharmaceutical business, head of the respiratory inhalation and biologics business unit, and head of Hong Kong and Macau.
At the same time as the business adjustment, the division of labor of the management team has also changed to a certain extent.
The new AstraZeneca China biopharmaceutical business will be led by Lin Xiao, the current general manager of AstraZeneca China biopharmaceutical business and head of Hong Kong and Macau; the current heads of the four major business teams of omnichannel and county, retail, community, and Eagle will report directly to Lin Xiao.
Liu Qian, general manager of AstraZeneca China's omnichannel business unit, is fully responsible for the respiratory and digestive business unit and serves as the general manager of AstraZeneca China's respiratory and digestive business unit; Chen Xi is the vice president of AstraZeneca China and the head of the respiratory and autologous immune biopharmaceuticals, vaccines and immunotherapy business units.
At the same time, Chen Xi will also serve as the head of the compliance and risk control coaching team to be established by AstraZeneca China, reporting to Lai Minglong, AstraZeneca's global senior vice president, general manager of China, and general manager of oncology business, and Lin Xiao, general manager of AstraZeneca China's biopharmaceutical business and head of Hong Kong and Macau.
Guan Dongmei, Vice President of AstraZeneca China and Head of the Cardiovascular, Renal and Metabolic Business Unit, continues to be fully responsible for the Cardiovascular, Renal and Metabolic Business Unit.

Chronic diseases such as tumors, respiratory, and digestive diseases have always been important areas of development for AstraZeneca and also its areas of strength.
The 2024 semi-annual report shows that AstraZeneca's revenue in the field of tumors reached nearly US$10.44 billion (an increase of nearly 22%), accounting for 42% of its total revenue; revenue in the field of respiratory and immune diseases reached nearly US$3.791 billion (an increase of nearly 22%); revenue in the field of cardiovascular, renal and metabolic diseases reached nearly US$6.22 billion (an increase of nearly 22%).
In the field of tumors, AstraZeneca has several blockbuster products, such as osimertinib, whose sales in the first half of this year reached nearly US$3.203 billion, a year-on-year increase of nearly 13%; sales of durvalumab reached nearly US$2.259 billion (a year-on-year increase of nearly 25%); sales of HER2 ADC de trastuzumab reached nearly US$932 million (a year-on-year increase of nearly 62%).
From the pipeline point of view, AstraZeneca currently has nearly 50 chronic disease clinical research and development pipelines in the field of chronic diseases in progress worldwide, and there are more than 20 new molecular drugs in the clinical pipeline. Specifically in China, AstraZeneca has introduced more than 10 innovative drugs in the field of chronic diseases.
AstraZeneca China said that with the normalization of centralized procurement and the influence of national policies such as tiered diagnosis and treatment, co-management in and out of hospitals in the field of chronic disease treatment has become one of the obvious industry trends at present.
Especially in the field of chronic diseases, the group of chronic disease patients has continued to expand. In recent years, AstraZeneca China has continuously adjusted and expanded its chronic disease layout.
Data show that the current number of people with cardiovascular diseases in my country has reached 330 million, the number of people with chronic kidney disease has reached 120 million, the number of people with diabetes has reached 141 million, and the number of people with chronic obstructive pulmonary disease has reached nearly 100 million.
While developing related chronic disease products, AstraZeneca China has successively carried out a series of cooperation.
For example, in March 2024, AstraZeneca invested another $475 million in Wuxi to build a small molecule drug factory; previously (in 2022), AstraZeneca increased investment in Wuxi to introduce a high potassium product production line and integrated the digestive injection production line.
At the investor day in May this year, AstraZeneca said that it would achieve a total revenue of $80 billion in 2030 and achieve sustained growth after 2030. It also revealed that 20 new drugs will be launched before 2030, and new drugs to be launched in the future include cyp11b2 small molecule baxdrostat, AZN ADCs, etc.

https://mp.weixin.qq.com/